Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.
The combination of pegylated interferon (PEG-IFN) and ribavirin is the standard treatment for chronic hepatitis C. Our recent clinical study suggests that ribavirin augments the induction of interferon-stimulated genes (ISGs) in patients treated for hepatitis C virus (HCV) infection. In order to further characterize the mechanisms of action of ribavirin, we examined the effect of ribavirin treatment on ISG induction in cell culture. In addition, the effect of ribavirin on infectious HCV cell culture systems was studied. Similar to interferon (IFN)-α, ribavirin potently inhibits JFH-1 infection of Huh7.5.1 cells in a dose-dependent manner, which spans the physiological concentration of ribavirin in vivo. Microarray analysis and subsequent quantitative polymerase chain reaction assays demonstrated that ribavirin treatment resulted in the induction of a distinct set of ISGs. These ISGs, including IFN regulatory factors 7 and 9, are known to play an important role in anti-HCV responses. When ribavirin is used in conjunction with IFN-α, induction of specific ISGs is synergistic when compared with either drug applied separately. Direct up-regulation of these antiviral genes by ribavirin is mediated by a novel mechanism different from those associated with IFN signaling and intracellular double-stranded RNA sensing pathways such as RIG-I and MDA5. RNA interference studies excluded the activation of the Toll-like receptor and nuclear factor κB pathways in the action of ribavirin.


CONCLUSIONS
Our study suggests that ribavirin, acting by way of a novel innate mechanism, potentiates the anti-HCV effect of IFN. Understanding the mechanism of action of ribavirin would be valuable in identifying novel antivirals.
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Emmanuel
E
Thomas
Jordan J
JJ
Feld
Qisheng
Q
Li
Zongyi
Z
Hu
Michael W
MW
Fried
T Jake
TJ
Liang
D004357:Drug Synergism; D006151:Guanosine / Q000494:pharmacology; D016174:Hepacivirus / Q000187:drug effects* / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D050839:Interferon Regulatory Factor-7 / Q000096:biosynthesis; D000077190:Interferon alpha-2; D050834:Interferon-Stimulated Gene Factor 3, gamma Subunit / Q000096:biosynthesis; D016898:Interferon-alpha / Q000494:pharmacology; D016328:NF-kappa B / Q000502:physiology; D044925:Oxidoreductases Acting on CH-CH Group Donors; D011092:Polyethylene Glycols / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism; D011994:Recombinant Proteins; D012254:Ribavirin / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D000090123:Viperin Protein
D006151:Guanosine; D050839:Interferon Regulatory Factor-7; D000077190:Interferon alpha-2; D050834:Interferon-Stimulated Gene Factor 3, gamma Subunit; D016898:Interferon-alpha; D016328:NF-kappa B; D044925:Oxidoreductases Acting on CH-CH Group Donors; D011092:Polyethylene Glycols; D011506:Proteins; D011994:Recombinant Proteins; D012254:Ribavirin; C494234:IRF7 protein, human; C494227:IRF9 protein, human; C444427:RSAD2 protein, human; D000090123:Viperin Protein; C100416:peginterferon alfa-2a
Gastroenterology. 2007 Jan;132(1):311-20
17241881
J Virol. 2004 Feb;78(3):1448-55
14722300
Cell. 2009 Oct 30;139(3):610-22
19879846
Nat Immunol. 2008 Apr;9(4):378-87
18345002
Gastroenterology. 2006 Nov;131(5):1452-62
17101321
Nat Med. 2005 Jul;11(7):791-6
15951748
Nature. 2005 Aug 18;436(7053):939-45
16107833
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900
11371613
Curr Top Microbiol Immunol. 2002;270:155-67
12467250
Nature. 2005 Aug 18;436(7053):967-72
16107837
Nature. 2004 Dec 16;432(7019):922-4
15602565
J Virol. 2007 May;81(9):4405-11
17301131
Clin Gastroenterol Hepatol. 2004 Apr;2(4):337-9
15067629
Gastroenterology. 2005 May;128(5):1437-44
15887125
Antivir Ther. 2008;13(4):607-11
18672540
Hepatology. 2009 Dec;50(6):1719-26
19852040
J Virol. 2009 May;83(9):4538-47
19244331
Virology. 2003 Jun 5;310(2):333-42
12781720
Virology. 1981 Apr 30;110(2):281-9
6111860
Ther Drug Monit. 2000 Oct;22(5):555-65
11034261
J Antimicrob Chemother. 2006 Jan;57(1):8-13
16293677
Br J Clin Pharmacol. 2006 Dec;62(6):699-709
17118125
Gastroenterology. 2010 Jul;139(1):154-62.e4
20303352
Curr Top Microbiol Immunol. 2007;316:233-50
17969451
Antivir Ther. 2010;15(4):633-9
20587856
Semin Liver Dis. 1999;19 Suppl 1:17-24
10349689
J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S73-8
17567473
J Biol Chem. 2001 Dec 7;276(49):46094-8
11602568
Trends Cell Biol. 1998 Oct;8(10):397-403
9789328
Gastroenterology. 2004 Mar;126(3):703-14
14988824
Hepatology. 2008 Oct;48(4):1033-43
18697207
Genes Cells. 1996 Jan;1(1):115-24
9078371
Am J Gastroenterol. 2006 Apr;101(4):842-7
16494584
J Virol. 2003 Jan;77(2):1092-104
12502825
Liver Int. 2009 Jan;29 Suppl 1:68-73
19207968
J Viral Hepat. 2008 Sep;15(9):651-8
18637076
PLoS Pathog. 2009 Jan;5(1):e1000269
19148281
Hepatology. 2003 Jul;38(1):66-74
12829988
Science. 1972 Aug 25;177(4050):705-6
4340949
Hepatology. 1998 May;27(5):1285-95
9581682
Methods Mol Med. 2005;117:99-113
16118448
Lancet. 2001 Sep 22;358(9286):958-65
11583749
J Virol. 2007 Apr;81(7):3391-401
17267482
Biochem Pharmacol. 2006 Oct 30;72(9):1102-13
16930560
J Virol. 2003 May;77(10):5933-47
12719586
J Biol Chem. 2007 Mar 9;282(10):7576-81
17204473
Nat Immunol. 2005 Oct;6(10):981-8
16127453
Immunity. 2000 Oct;13(4):539-48
11070172
Nat Med. 2000 Dec;6(12):1375-9
11100123
Hepatology. 2005 Feb;41(2):275-9
15660393
Science. 2010 Jan 8;327(5962):198-201
19965718
N Engl J Med. 2006 Dec 7;355(23):2444-51
17151366
Hepatology. 2003 Oct;38(4):869-78
14512874
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
Nature. 2005 Apr 7;434(7034):772-7
15800576
J Virol. 2005 Mar;79(5):2689-99
15708988
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9294-9
15939869
Nat Rev Drug Discov. 2007 Dec;6(12):975-90
18049472
J Hepatol. 1999 Mar;30(3):376-82
10190717
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12884-9
17616579
Hepatology. 2007 Nov;46(5):1548-63
17929300
Liver Int. 2008 Dec;28(10):1332-43
19055642